Latest News - Phase 3/4 Trials

Tuesday, December 05, 2017 | Phase 3/4 Trials,, Research and Publications

Revance: RT002 Achieves 6-Month Duration in Phase 3

  Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in …

Read the full story

Wednesday, November 08, 2017 | Phase 3/4 Trials,

Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors

Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and sympt…

Read the full story

Friday, October 27, 2017 | Phase 3/4 Trials,, Research and Publications, AbbVie

Abbvie's Risankizumab Performs Well in Three Phase Three Psoriasis Studies

Top-line results from three pivotal Phase 3 clinical trials show that  risankizumab, an investigational interleukin-23 (IL-23) inhibitor, met the co-primary endpoints of at least a 90 percent imp…

Read the full story

Tuesday, September 26, 2017 | Personnel/Company News, Phase 3/4 Trials,, Novan

Novan Has Guidance Meeting with FDA on SB204

Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which t…

Read the full story

Wednesday, September 20, 2017 | Phase 3/4 Trials,, Research and Publications

Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasis

New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate…

Read the full story

Wednesday, September 13, 2017 | Phase 3/4 Trials,, Novartis

Five-Year Data Show Sustained Efficacy, Safety for Cosentyx

Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase …

Read the full story

Monday, September 11, 2017 | Phase 3/4 Trials,,, Research and Publications

Lilly to Present New Data for Olumiant® and Taltz® at EADV

Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation …

Read the full story

Thursday, September 07, 2017 | Phase 3/4 Trials,, Research and Publications

Dermira Presents New Data on Late-Stage Programs at European Dermatology Congress

Dermira, Inc. will present data from its glycopyrronium tosylate (formerly DRM04) and Cimzia (certolizumab pegol) Phase 3 clinical programs in poster sessions at the 26th European Academy of Dermatolo…

Read the full story

Thursday, August 31, 2017 | FDA Approval/Clearance, Healthcare Trends, Phase 3/4 Trials,,, Product Launches and Updates, Research and Publications

GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologics

The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of t…

Read the full story

Thursday, August 03, 2017 | Phase 3/4 Trials,

Aclaris Submits Marketing Authorization Application in Europe for A-101 40% for Seborrheic Keratosis

Aclaris Therapeutics, Inc. has submitted a Marketing Authorization Application (MAA) with the Medicines Product Agency (MPA) in Sweden for its product candidate A-101 40% Topical Solution for the trea…

Read the full story

Monday, July 17, 2017 | Phase 3/4 Trials

Paratek: Phase 3 Study of Oral-Only Dosing of Omadacycline Met FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections

Paratek Pharmaceuticals, Inc. shared positive top-line results from a pivotal Phase 3 study comparing its once-daily, oral investigational antibiotic, omadacycline, to twice-daily oral linezolid in th…

Read the full story

Wednesday, July 05, 2017 | Phase 3/4 Trials,

Array BioPharma Submits NDAs for Binimetinib and Encorafenib in Advanced Melanoma

Array BioPharma submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once da…

Read the full story

Thursday, June 15, 2017 | Phase 3/4 Trials,

PsA Patients Failing Anti-TNF Drugs May Do Well on Taltz

New data show that Taltz (ixekizumab) improved the signs and symptoms of active psoriatic arthritis (PsA) in patients who had inadequate response to one or two TNF inhibitors or were intolerant o…

Read the full story

Wednesday, June 07, 2017 | Phase 3/4 Trials,, Sun Pharmaceutical Industries Ltd

Tildrakizumab Performs Well in Two Phase 3 Psoriasis Studies

Two Phase 3 trials show that tildrakizumab is efficacious and well-tolerated in patients with moderate-to-severe chronic plaque psoriasis. Specifically more than 60 percent of all patients who rece…

Read the full story

Monday, April 24, 2017 | Phase 3/4 Trials,, Research and Publications

Paratek: Phase 3 Data Show Omadacycline Effective Against Common Skin Pathogens, Including MRSA

Analysis of microbiology data from a Phase 3 study of omadacycline in acute skin infections shows that once-daily treatment with IV-to-oral omadacycline is effective in treating the most frequently is…

Read the full story
Load More